Actinogen Medical completed the main phase of its XanaMIA Phase 2b/3 Alzheimer's trial, with topline results expected in November. The trial tests Xanamem 10 mg daily in mild to moderate Alzheimer's patients, focusing on cognitive outcomes. The company has a pro-forma cash position of about A$21.9 million, supported by recent option exercises and a tax rebate, providing funding into late 2027 or 2028. If results are positive, Actinogen plans to advance regulatory steps and a final pivotal trial, likely with partners.
Actinogen Medical's XanaMIA trial progress is noted here with Pluang's Health sector snapshot as of Oct 19, 2026 05:21 WIB: Out of 150 priced Health-sector US stocks, 29 rose and 118 fell. Among notable movers, FLNA (Cassava Sciences Inc) declined 7.53% to USD 0.70 with a typical hold time of 38 days, TMDX (TransMedics Group Inc) dropped 7.50% to USD 70.78, and IOVA (Iovance Biotherapeutics Inc.) fell 7.47% to USD 13.62. The most notable figure is the 118 stocks that declined today.
FREELANDER participated in the 2026 Chery International User Summit in Wuhu, China, showcasing the international variant of its FREELANDER 8 model through a day-and-night program on October 19. The day featured the first international test drive on c...
Disc Medicine announced a webcast on October 19, 2026, to discuss topline results from its APOLLO Phase 3 trial of bitopertin, an investigational oral drug for erythropoietic protoporphyria (EPP). Bitopertin targets glycine transporter 1 to modulate ...
Ethena (ENA) saw a notable price increase of 9.15% over four hours, reaching $0.1921 on the Binance spot ENA/USDT pair as of October 18. Despite a smaller 24-hour gain of 2.07%, the short-term surge highlights increased trading activity. During the s...
An unidentified large trader's short position on Ether (ETH) valued at $26.64 million faced partial liquidation after the ETH price rebounded to $2,409. The short was initially opened at $2,366 involving 13,830 ETH worth $32.72 million. During the pr...
A short position on Ether (ETH) involving 2,765 ETH, valued at $6.66 million, was partially liquidated on Sunday as the price of ETH rose to $2,409. The short had opened at a price of $2,366 with a total value of $32.72 million. By the evening, the p...
